Rahway, NJCIK 3101584 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
12 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Personalis Inc | 14.04M | $111.80M | 40.5% | 0 | Held |
| 2 | Moderna Inc | 2.31M | $68.07M | 24.6% | 0 | Held |
| 3 | Kymera Therapeutics Inc | 772.2K | $60.08M | 21.7% | 0 | Held |
| 4 | Entrada Therapeutics Inc |
| 1.74M |
| $17.88M |
| 6.5% |
| 0 |
| Held |
| 5 | Evaxion Biotech | 1.21M | $5.79M | 2.1% | 0 | Held |
| 6 | Alector Inc | 3.55M | $5.53M | 2.0% | 0 | Held |
| 7 | Sutro Biopharma Inc | 272.4K | $3.15M | 1.1% | −2.45M | Reduced |
| 8 | Viridian Therapeutics Inc | 93.4K | $2.91M | 1.1% | 0 | Held |
| 9 | Xilio Therapeutics Inc | 1.48M | $949.9K | 0.3% | 0 | Held |
| 10 | Carisma Therapeutics Inc | 1.47M | $63.3K | 0.0% | 0 | Held |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio